Results 111 to 120 of about 303,632 (262)
HemaSphere, Volume 10, Issue 3, March 2026.Abstract TP53 mutations are found in over 50% of tumor types, including myeloproliferative neoplasms (MPNs). MPNs are characterized by a chronic phase, which may progress to secondary acute myeloid leukemia (sAML). Here, we discuss the physiological functions of p53 in hematopoiesis and its deregulation in MPNs.
Suzana da Silva‐Benedito +6 more
wiley +1 more source
Improved Diagnosis of the Transition to JAK2V617F Homozygosity: The Key Feature for Predicting the Evolution of Myeloproliferative Neoplasms [PDF]
, 2013 Most cases of BCR-ABL1-negative myeloproliferative neoplasms (MPNs), essential thrombocythemia, polycythemia vera and primary myelofibrosis are associated with JAK2V617F mutations.
Bianchini, Michele +6 more
core +3 more sources
Updates in the management of polycythemia vera and essential thrombocythemia
Therapeutic Advances in Hematology, 2019 Polycythemia vera (PV) and essential thrombocythemia (ET) are both classic, relatively indolent, chronic Philadelphia-chromosome-negative (Ph−) myeloproliferative neoplasms (MPNs) characterized by elevated blood counts, thrombotic as well as hemorrhagic ...
P. Bose, S. Verstovsek
semanticscholar +1 more source
Annals of Saudi Medicine, 2016 Polycythemia vera is a Philadelphia chromosome-negative myeloproliferative neoplasm. Chronic lymphocytic leukemia is a monoclonal expansion of a CD5+ CD19+ B lymphocytes.
Serdal Korkmaz +4 more
doaj +1 more source
GAMBARAN GEN JAK2 PADA PENDERITA POLISITEMIA VERA DI LABORATORIUM CEBIOR [PDF]
, 2015 Background: Polycythemia vera ( PV ) is one of the myeloproliferative malignancies. The Jak2V617F mutation is found in approximately 96 percent of people with PV. JAK2 gene mutation results in the production of an activated JAK2 protein, which appears to
Faradz, Sultana MH +2 more
core +1 more source
Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage. [PDF]
, 2018 Somatic mutations in the endoplasmic reticulum chaperone calreticulin (CALR) are detected in approximately 40% of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF).
Aungier, Juliet +17 more
core +1 more source
Clinical Lymphoma, Myeloma & Leukemia, 2019 Approximately half of the patients with polycythemia vera experience substantial symptom burdens. We analyzed data from the ongoing Prospective Observational Study of Patients with Polycythemia Vera in US Clinical Practices (REVEAL) study to evaluate the
M. Grunwald +10 more
semanticscholar +1 more source
Detection of JAK2 exon 12 mutations in 15 patients with JAK2V617F negative polycythemia vera
Haematologica, 2009 To further characterize JAK2 exon 12 mutations, we performed molecular screening in 409 patients with polycythemia vera or unclear erythrocytosis with unmutated JAK2V617. The frequency of JAK2exon12 mutations was 10/63 (15.9%) in PV but only 5/346 (1.4%)
Susanne Schnittger +14 more
doaj +1 more source
The SMAC mimetic LCL-161 selectively targets JAK2V617F mutant cells. [PDF]
, 2020 Background:Evasion from programmed cell death is a hallmark of cancer and can be achieved in cancer cells by overexpression of inhibitor of apoptosis proteins (IAPs).
Craver, Brianna M +6 more
core
Polycythemia vera treatment algorithm 2018
Blood Cancer Journal, 2018 Recently reported mature survival data have confirmed the favorable prognosis in polycythemia vera (PV), with an estimated median survival of 24 years, in patients younger than age 60 years old.
A. Tefferi, A. Vannucchi, T. Barbui
semanticscholar +1 more source